GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Owner Earnings per Share (TTM)

ENVB (Enveric Biosciences) Owner Earnings per Share (TTM) : -19.47 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Enveric Biosciences's Owner Earnings per Share (TTM) ended in Sep. 2024 was $-19.47. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Enveric Biosciences's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Enveric Biosciences was 114.42. The lowest was 15.50. And the median was 25.25.


ENVB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.695
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Enveric Biosciences's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-3.60. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-38.55. It's PE Ratio (TTM) ratio for today is At Loss.

Enveric Biosciences's EPS without NRI for the three months ended in Sep. 2024 was $-3.60. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-42.89. It's PE Ratio without NRI ratio for today is At Loss.


Enveric Biosciences Owner Earnings per Share (TTM) Historical Data

The historical data trend for Enveric Biosciences's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Owner Earnings per Share (TTM) Chart

Enveric Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,329.66 -983.18 -1,104.91 -136.00 -116.01

Enveric Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -155.22 -116.01 -56.63 -24.66 -19.47

Competitive Comparison of Enveric Biosciences's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Enveric Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Price-to-Owner-Earnings falls into.


;
;

Enveric Biosciences Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Enveric Biosciences's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -9.86
Depreciation, Depletion and Amortization 0.34
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.68
Change In Working Capital -1.10
Shares Outstanding (Diluted Average) 0.58

1. Start with "Net Income" from income statement. Enveric Biosciences's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.86 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Enveric Biosciences's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2024 was $0.34 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Enveric Biosciences's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.68 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Enveric Biosciences's 5-Year Average Maintenance Capital Expenditure = $0.68 Mil

5. "Change In Working Capital" is from cashflow statement. Enveric Biosciences's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.10 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Enveric Biosciences's Shares Outstanding (Diluted Average) for the months ended in Sep. 2024 was 0.580 Mil.

Enveric Biosciences's Onwer Earnings Per Share for Sep. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -9.856 +0.339+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.68169643592913+-1.095)/0.580
=-19.47

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.47/-19.47
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Enveric Biosciences Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences Business Description

Traded in Other Exchanges
N/A
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103